Aurinia Pharmaceuticals (TSE:AUP) (NASDAQ:AUPH) will be posting its quarterly earnings results after the market closes on Thursday, November 8th. Analysts expect Aurinia Pharmaceuticals to post earnings of C($0.23) per share for the quarter.
Aurinia Pharmaceuticals (TSE:AUP) (NASDAQ:AUPH) last released its earnings results on Thursday, August 9th. The company reported C($0.25) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of C($0.21) by C($0.04). The business had revenue of C$0.04 million for the quarter, compared to analysts’ expectations of C$0.07 million.
Aurinia Pharmaceuticals stock opened at C$7.48 on Wednesday. Aurinia Pharmaceuticals has a 52 week low of C$5.68 and a 52 week high of C$8.65.
TRADEMARK VIOLATION WARNING: “Aurinia Pharmaceuticals (AUP) to Release Earnings on Thursday” was published by Enterprise Leader and is the property of of Enterprise Leader. If you are accessing this report on another publication, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this report can be read at https://theenterpriseleader.com/2018/11/07/aurinia-pharmaceuticals-aup-to-release-earnings-on-thursday.html.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.